Introduction
============

COPD is a complex respiratory disorder characterized by persistent respiratory symptoms and airflow limitation.[@dkz221-B1] The chronic and progressive course of COPD is frequently aggravated by exacerbation, defined as an acute worsening of respiratory symptoms, such as increased cough, dyspnoea and production of sputum.[@dkz221-B2] Exacerbations of COPD can be triggered by respiratory tract infections; 40%--60% of exacerbations are caused by bacteria, especially *Haemophilus influenzae, Streptococcus pneumoniae* and *Moraxella catarrhalis.*[@dkz221-B3] Evidence from randomized controlled trials indicated that use of antibacterials (ABs) may reduce the frequency and severity of COPD exacerbations.[@dkz221-B4] Therefore, guidelines have recommended involving ABs in the therapeutic and preventive management of COPD exacerbations.[@dkz221-B1]^,^[@dkz221-B7]

Patients with COPD often suffer from multiple morbidities.[@dkz221-B8] Hence, polypharmacy is common and contributes to drug--drug interactions (DDIs). Adverse drug reactions (ADRs) or therapeutic failure may be the result of interactions between ABs and co-administered drugs. In addition, COPD is an age-related disease and the elderly are more susceptible to the effect of DDIs because of gradual physiological changes affecting pharmacokinetics and pharmacodynamics.[@dkz221-B9]

The objectives of this study were to: (i) systematically review DDIs related to frequently prescribed ABs among COPD patients from observational and clinical studies; and (ii) improve AB prescribing safety in clinical practice by structuring DDIs according to comorbidities of COPD. Studies without comparison groups, and therefore with low quality of the causal evidence, such as case reports about QT-interval prolonging interactions, are not included in this review. A DDI handbook such as *Stockley's Drug Interactions* and the official product information should be referred to for the clinical impact of these kinds of interaction.

Methods
=======

Search strategy
---------------

We conducted a systematic review following the PRISMA guideline. PubMed and Embase databases were searched for related articles published in English up to 8 February 2018 using key terms 'drug interactions', 'pharmacokinetics' and 'pharmacodynamics', and a list of most frequently used ABs for COPD (Table [1](#dkz221-T1){ref-type="table"}). The ABs were selected based on two related Cochrane reviews and their prescription frequency in the University of Groningen prescription database IADB.nl (<http://www.iadb.nl/>) covering drug prescriptions for ∼700000 people.[@dkz221-B4]^,^[@dkz221-B5] Additionally, we checked the primary sources of signals from Dutch DDI alert systems: G-Standard and Pharmabase.[@dkz221-B10] Reference lists from eligible studies were also tracked for additional qualified papers. Full search details are provided in the [Supplementary data](#sup1){ref-type="supplementary-material"}, available at *JAC* Online.

###### 

ABs included in the study that are frequently prescribed among COPD patients[^a^](#tblfn1){ref-type="table-fn"}

  Category       Sub-category      ABs included
  -------------- ----------------- --------------------------------------------------------------------------------------------------------------------------------
  β-Lactam       penicillin        amoxicillin/clavulanic acid (co-amoxiclav), amoxicillin, flucloxacillin, pheneticillin, phenoxymethylpenicillin (penicillin V)
                 cephalosporin     cefaclor, cefuroxime, ceftriaxone, cefradine, ceftazidime
  Macrolide                        erythromycin, clarithromycin, azithromycin, roxithromycin, clindamycin
  Tetracycline                     tetracycline, doxycycline, minocycline
  Quinolone      fluoroquinolone   ciprofloxacin, moxifloxacin, levofloxacin, ofloxacin, norfloxacin
                 other quinolone   pipemidic acid
  Sulphonamide                     sulfamethoxazole
  Others                           nitrofurantoin, methenamine, trimethoprim

Based on two Cochrane reviews[@dkz221-B4]^,^[@dkz221-B5] and use within the University of Groningen (the Netherlands) prescription database, IADB.nl (<http://www.iadb.nl/>).

Study selection criteria
------------------------

Eligible studies met the following criteria: (i) DDIs in humans; (ii) involving the targeted ABs; and (iii) being clinical trials, randomized controlled trials or cohort or case--control studies. We excluded case reports and other descriptive studies. We further excluded studies with subjects whose pharmacokinetics and pharmacodynamics were not comparable to those of general COPD patients, e.g. newborn babies, pregnant women and patients with severe renal/hepatic impairment. Other exclusion criteria were: (i) unregistered drugs (by FDA or EMA); (ii) involving three or more drug interactions; and (iii) not DDIs (food--drug or gene--drug interactions); (iv) not original studies (reviews, letters and editorials). Pharmacodynamic interactions were beyond the scope of this review and were excluded.

Data extraction and quality assessment
--------------------------------------

All records were exported to Refworks; titles and abstracts were screened by Y. W. and A. M. E. J. independently. Full-text papers were obtained for records that were considered of potential relevance by at least one of the reviewers. Final decisions were made by consensus between two reviewers according to the preset criteria. Discrepancies between reviewers were resolved by discussion; a third reviewer (E. H.) was asked if no consensus was reached. Information about names of ABs and related interacting drugs, study design, study subjects, sample size, interacting mechanism, effects of interaction and recommendation by study authors were extracted by the same reviewers (Y. W. and A. M. E. J.) and checked by another reviewer (M. A. B.). Quality of evidence was evaluated by grading 0--4 based on criteria (Table [2](#dkz221-T2){ref-type="table"}) used by previous studies.[@dkz221-B11]^,^[@dkz221-B12]

###### 

Quality of evidence for DDIs[@dkz221-B11]^,^[@dkz221-B12]

  Definition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Score
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  Clinical research with appropriate control group and relevant pharmacokinetics and/or pharmacodynamic parameters. The studies meet all of the criteria below: The interacting effect of concomitant medication with investigated drugs is reported in the manuscript.All potential confounders are mentioned and taken into account (for example smoking behaviour or renal function).The results of interaction are based on the steady-state kinetics.Variation in dose was adjusted.   4
  Clinical research with appropriate control group and relevant pharmacokinetics and/or pharmacodynamic parameters that does not meet one or more of the pre-defined criteria above.                                                                                                                                                                                                                                                                                                        3
  Complete observational studies with clinically relevant results.                                                                                                                                                                                                                                                                                                                                                                                                                          2
  Incomplete observational studies. (e.g. without controlling confounders or presence of other explanatory factors for the adverse reaction), case reports, summary of product characteristics.                                                                                                                                                                                                                                                                                             1
  *In vitro* studies, *in vivo* animal studies, prediction modelling studies.                                                                                                                                                                                                                                                                                                                                                                                                               0

The strengths of the DDIs were classified into four levels (1, strong; 2, substantial; 3, moderate; 4, weak/no) according to preset published criteria (Table [3](#dkz221-T3){ref-type="table"}).[@dkz221-B12] In the cases of several studies on the same DDI combination, we categorized the DDI based on the highest level of severity. Considering that drugs with a narrow therapeutic index (NTI) are more vulnerable to DDIs, the strength of the DDI for such drugs was upgraded one level.[@dkz221-B12]

###### 

Description of level of DDIs[@dkz221-B10]

  Definition                                                                                                                             AUC            Clearance        Score[^a^](#tblfn3){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------- -------------- -------------------- ------------------------------------------
  Involved inhibitor                                                                                                                   \>200% ↑          ↓ \>67%                            1
  Involved inducer                                                                                                                     \>90% ↓           ↑ ≥900%                            1
  For observational studies, RR/OR ≥10                                                                                                                                                      1
  Involved inhibitor                                                                                                                 75%--200% ↑     ↓ ≥43% to \<67%                        2
  Involved inducer                                                                                                                    60%--90% ↓    ↑ ≥150% to \<900%                       2
  For observational studies, RR/OR 3--9                                                                                                                                                     2
  Involved inhibitor                                                                                                                  25%--75% ↑     ↓ ≥20% to \<43%                        3
  Involved inducer                                                                                                                    25%--60% ↓     ↑ ≥33% to \<150%                       3
  For observational studies, RR/OR 1.5--2.9                                                                                                                                                 3
  Involved inducer/inhibitor                                                                                                         \<25% change   ↓ \<20% or ↑ \<33%                      4
  For observational studies, RR/OR \<1.5                                                                                                                                                    4
   (a) For interacting drugs with an NTI, the degree of DDIs will be improved to the level one higher                                                                                   exception
   (b) If the DDI level cannot be judged by the above criteria, we assessed it by discussion based on available data and evidence                                                       exception

RR, relative risk; OR, odds ratio; ↑, increase; ↓, decrease.

1, strong interaction; 2, substantial interaction; 3, moderate interaction; and 4, weak/no interaction.

Results
=======

Publications identified by literature search
--------------------------------------------

Our search yielded 1412 and 1734 studies from PubMed and Embase, respectively (Figure [1](#dkz221-F1){ref-type="fig"}). After removing duplicates, 2560 articles were screened by title and abstract, of which 630 papers were included for full-text screening, resulting in 282 eligible articles. With 36 studies identified from other resources, we finally obtained 318 studies for assessment in this review.

![Flow chart of study selection.](dkz221f1){#dkz221-F1}

The interacting drugs, underlying mechanisms, levels and practice recommendations for the DDIs are presented in Table [4](#dkz221-T4){ref-type="table"}. Details on individual studies of DDIs with a potential clinical significance (levels 1--3) are presented in Tables [S1 and S2](#sup1){ref-type="supplementary-material"} and the data on studies with a low level of DDIs (weak or no interaction) are presented in Table [S3](#sup1){ref-type="supplementary-material"}.

###### 

DDIs of antibacterials (ABs) for COPD exacerbation and other drugs for treating its comorbidities

  Comorbidity                                                                                            Medication                                                 Interacting AB                                                                                     Mechanism                                                                                                                       Management suggestions                                                                                                                                        Level of interaction[^a^](#tblfn6){ref-type="table-fn"}                                  Reference
  ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------- -------------------------------------------------------------------------
  *Diabetes Antidiabetic medication*                                                                     glipizide, glyburide                                       TMP/SMX                                                                                            Inhibition of CYP2C9.                                                                                                           Consider alternative or adjusted dose of substrate or use cautiously by monitoring patient\'s blood glucose.                                                                             2                                                           [@dkz221-B16]
  glyburide                                                                                              clarithromycin                                             Inhibition of P-gp.                                                                                                                                                                                                                                                                                                                                                                                                                                       
  glipizide, glyburide                                                                                   levofloxacin                                               Inhibition of P-gp.                                                                                Monitor patient\'s blood glucose and if necessary adjust dose of substrate.                                                     3                                                                                                                                                                         [@dkz221-B16] ^,^ [@dkz221-B20]              
  tolbutamide                                                                                            clarithromycin                                             Inhibition of CYP3A4 and P-gp.                                                                                                                                                                                                                                                                                                                                                                                                                            
  TMP/SMX                                                                                                Inhibition of CYP2C9.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  glipizide, repaglinide                                                                                 clarithromycin                                             Inhibition of CYP3A4.                                                                                                                                                                                                                                                                                                                                                                                                                                     
  repaglinide, rosiglitazone                                                                             TMP/SMX                                                    Inhibition of CYP2C8.                                                                                                                                                                                                                                                                                                                                                                                                                                     
  metformin                                                                                              TMP/SMX                                                    Inhibition of OCT2 and MATE1.                                                                                                                                                                                                                                                                                                                                                                                                                             
  Heart and circulatory system diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *Antihypertensive agents*                                                                              spironolactone                                             TMP/SMX                                                                                            Inhibition of potassium secretion.                                                                                              Avoid combination or adjust dose of substrates and closely monitor potassium plasma levels.                                                                                              1                                                           [@dkz221-B32]
  calcium channel blocker                                                                                erythromycin, clarithromycin                               Inhibition of CYP3A4.                                                                              Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects.                               2                                                                                                                                                                                  [@dkz221-B27]                       
  azithromycin                                                                                           Inhibition of CYP3A4.                                      Monitor side effects and if necessary adjust dose of substrate.                                    3                                                                                                                               [@dkz221-B27]                                                                                                                                                                                                          
  *Lipid-lowering drugs*                                                                                 simvastatin                                                erythromycin                                                                                       Inhibition of CYP3A4.                                                                                                           Avoid combination or adjust dose of substrates and closely monitor side effects.                                                                                                         1                                                           [@dkz221-B34]
  atorvastatin                                                                                           clarithromycin                                             Inhibition of CYP3A4.                                                                              Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects.                               2                                                                                                                                                                                  [@dkz221-B35]                       
  erythromycin                                                                                           Inhibition of CYP3A4.                                      Monitor side effects and if necessary adjust dose of substrate.                                    3                                                                                                                               [@dkz221-B36] ^,^ [@dkz221-B204]                                                                                                                                                                                       
  rosuvastatin/pravastatin/fluvastatin                                                                   clarithromycin                                             Inhibition of OAT.                                                                                                                                                                                                                                                                                                                                                                                                                                        
  *Oral anticoagulants*                                                                                  warfarin, phenprocoumon /acenocoumarol                     TMP/SMX                                                                                            Inhibition of CYP2C9.                                                                                                           Avoid combination or closely monitor the change of INR routinely and adjust dose if needed.                                                                                              1                                                           [@dkz221-B39]
  amoxicillin/co- amoxiclav, ceftriaxone                                                                 Alterations in normal gut flora.                           Choose alternative AB or, if not possible, monitor the change of INR routinely.                    2                                                                                                                                                                                                                                                                                                                                                      
  clarithromycin, azithromycin, ciprofloxacin, levofloxacin, ofloxacin, doxycycline                      Inhibition of CYP3A4 or alterations in normal gut flora.                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  edoxaban, dabigatran, rivaroxaban                                                                      erythromycin, clarithromycin                               Inhibition of CYP3A4 and/or P-gp.                                                                  Consider alternative or adjusted dose of substrate or monitor signs of excessive anticoagulant effect.                          2                                                                                                                                                                         [@dkz221-B62] ^,^ [@dkz221-B63]              
  warfarin                                                                                               moxifloxacin                                               Inhibition of CYP3A4 or alterations in normal gut flora.                                           Monitor the change of INR routinely.                                                                                            3                                                                                                                                                                                  [@dkz221-B41]                       
  *Antiarrhythmic agents*                                                                                digoxin                                                    clarithromycin                                                                                     Inhibition of P-gp.                                                                                                             Avoid combination or perform TDM and if necessary adjust dose of substrate.                                                                                                              1                                                           [@dkz221-B68]
  quinidine, lignocaine                                                                                  erythromycin                                               Inhibition of CYP3A4.                                                                              Consider alternative or perform TDM and if necessary adjust dose of substrate.                                                  2                                                                                                                                                                                  [@dkz221-B64]                       
  procainamide                                                                                           TMP                                                        Inhibition of tubular secretion.                                                                                                                                                                                                                                                                                                                                                                                                                          
  pindolol, digoxin                                                                                      TMP/SMX                                                    Inhibition of tubular secretion.                                                                   Perform TDM and if necessary adjust dose of substrate.                                                                          3                                                                                                                                                                                  [@dkz221-B72]                       
  procainamide                                                                                           levofloxacin, ofloxacin                                    Inhibition of OCT.                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Respiratory diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  *Medication for obstructive airways diseases*                                                          methylprednisolone, montelukast                            clarithromycin                                                                                     Inhibition of CYP3A4 and P-gp.                                                                                                  Consider alternative or adjusted dose of substrate or use cautiously by monitoring side effects. For theophylline, perform TDM.                                                          2                                                  [@dkz221-B78] ^,^ [@dkz221-B90]
  theophylline                                                                                           erythromycin                                               Inhibition of CYP3A4.                                                                                                                                                                                                                                                                                                                                                                                                                                     
  ciprofloxacin                                                                                          Inhibition of CYP1A2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  loratadine                                                                                             erythromycin, clarithromycin                               Inhibition of CYP3A4.                                                                              Monitor side effects and if necessary adjust dose of substrate.                                                                 3                                                                                                                                                                         [@dkz221-B86] ^,^ [@dkz221-B87]              
  roflumilast                                                                                            erythromycin                                               Inhibition of CYP3A4.                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *Anti-TB drugs*                                                                                        rifabutin                                                  clarithromycin                                                                                     Inhibition of CYP3A4.                                                                                                           Avoid combination.                                                                                                                                                                       1                                       [@dkz221-B101] ^,^ [@dkz221-B110] ^,^ [@dkz221-B111]
  rifampicin, rifabutin                                                                                  clarithromycin                                             Induction of CYP3A4.                                                                               Consider alternative AB for COPD                                                                                                2                                                                                                                                                                        [@dkz221-B100] ^,^ [@dkz221-B101]             
  rifampicin, rifabutin                                                                                  TMP/SMX, doxycycline                                       Induction of CYP3A4/CYP2C9.                                                                        Consider alternative AB for COPD or monitor the effectiveness of AB and if necessary adjust dose of AB.                         3                                                                                                                                                                        [@dkz221-B102] ^,^ [@dkz221-B106]             
  rifampicin                                                                                             TMP/SMX                                                    Inhibition of mixed oxidases.                                                                                                                                                                                                                                                                                                                                                                                                                             
  moxifloxacin                                                                                           Induction of phase II enzymes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Neurological disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  *Anti-Parkinson's agents*                                                                              bromocriptine                                              erythromycin                                                                                       Inhibition of CYP3A4.                                                                                                           Avoid combination or adjust dose of substrates and closely monitor side effects.                                                                                                         1                                                          [@dkz221-B112]
  cabergoline                                                                                            clarithromycin                                             Inhibition of CYP3A4 and P-gp.                                                                     Consider alternative or adjusted dose of substrate or use cautiously by monitoring side effects.                                2                                                                                                                                                                                 [@dkz221-B113]                       
  *Antiepileptic drugs*                                                                                  carbamazepine, phenytoin                                   doxycycline                                                                                        Induction of CYP3A4.                                                                                                            Consider alternative or perform TDM.                                                                                                                                                     2                                                 [@dkz221-B116] ^,^ [@dkz221-B117]
  carbamazepine                                                                                          ciprofloxacin                                              Inhibition of CYP3A4/1A2.                                                                          Consider alternative or perform TDM.                                                                                            2                                                                                                                                                                                 [@dkz221-B118]                       
  phenytoin                                                                                              TMP/SMX                                                    Inhibition of CYP2C8.                                                                              Consider alternative or perform TDM.                                                                                            2                                                                                                                                                                        [@dkz221-B116] ^,^ [@dkz221-B119]             
  phenobarbital                                                                                          doxycycline                                                Induction of CYP3A4.                                                                               Monitor side effects and if necessary adjust dose of substrate.                                                                 3                                                                                                                                                                                 [@dkz221-B115]                       
  Depression and psychiatric disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  *Antidepressant, anxiolytic and antipsychotic agents*                                                  buspirone                                                  erythromycin                                                                                       Inhibition of CYP3A4.                                                                                                           Avoid combination or adjust dose of substrates and closely monitor side effects.                                                                                                         1                                                          [@dkz221-B125]
  quetiapine                                                                                             erythromycin                                               Inhibition of CYP3A4.                                                                              Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects. For clozapine, perform TDM.   2                                                                                                                                                                        [@dkz221-B122] ^,^ [@dkz221-B129]             
  pimozide, trazodone                                                                                    clarithromycin                                             Inhibition of CYP3A4.                                                                                                                                                                                                                                                                                                                                                                                                                                     
  clozapine                                                                                              ciprofloxacin                                              Inhibition of CYP1A2.                                                                                                                                                                                                                                                                                                                                                                                                                                     
  diazepam                                                                                               ciprofloxacin                                              Inhibition of CYP3A4.                                                                              Monitor side effects and if necessary adjust the dose of substrate.                                                             3                                                                                                                                                                                 [@dkz221-B127]                       
  Dyspepsia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  *Antidyspepsia medications*                                                                            aluminium hydroxide, sucralfate                            quinolone, tetracyclines                                                                           Complex formation.                                                                                                              Avoid combination or administer quinolone at least 2 h before or 6 h after co-agents.                                                                                                    1                                                          [@dkz221-B131]
  lansoprazole                                                                                           clarithromycin                                             Inhibition of CYP3A4.                                                                              Consider alternative or adjusted dose of substrate or use cautiously by monitoring side effects.                                2                                                                                                                                                                                 [@dkz221-B147]                       
  calcium carbonate                                                                                      quinolone, tetracyclines                                   Complex formation.                                                                                 Avoid co-administration or administer at interval of at least 2 h.                                                              2                                                                                                                                                                        [@dkz221-B131] ^,^ [@dkz221-B139]             
  bismuth subsalicylate                                                                                  quinolone, tetracyclines                                   Complex formation.                                                                                 Administration interval of at least 2 h.                                                                                        3                                                                                                                                                                        [@dkz221-B143] ^,^ [@dkz221-B205]             
  HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  *Anti-HIV drugs*                                                                                       didanosine                                                 ciprofloxacin                                                                                      Complex formation.                                                                                                              Avoid combination or administer quinolone at least 2 h before or 6 h after co-agents.                                                                                                    1                                                 [@dkz221-B149] ^,^ [@dkz221-B150]
  saquinavir                                                                                             erythromycin                                               Inhibition of CYP3A4.                                                                              Consider alternative or adjusted dose of substrate or use cautiously by monitoring side effects.                                2                                                                                                                                                                                 [@dkz221-B151]                       
  lamivudine, didanosine                                                                                 TMP/SMX                                                    Inhibition of tubular secretion.                                                                   Monitor side effects and if necessary adjust dose of substrate.                                                                 3                                                                                                                                                                        [@dkz221-B152] ^,^ [@dkz221-B153]             
  Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *Pulmonary arterial hypertension medications*                                                          bosentan                                                   clarithromycin                                                                                     Inhibition of CYP3A4 and P-gp.                                                                                                  Avoid combination or adjust dose of substrates and closely monitor side effects.                                                                                                         1                                                          [@dkz221-B206]
  ambrisentan                                                                                            clarithromycin                                             Inhibition of CYP3A4 and P-gp.                                                                     Monitor side effects and if necessary adjust dose of substrate.                                                                 3                                                                                                                                                                                 [@dkz221-B207]                       
  *Insomnia medications*                                                                                 brotizolam, triazolam, zopiclone                           erythromycin                                                                                       Inhibition of CYP3A4.                                                                                                           Consider an alternative AB or other hypnotic drugs (not a CYP3A4 substrate).                                                                                                             2                                                          [@dkz221-B208]
  zolpidem                                                                                               ciprofloxacin                                              Inhibition of CYP3A4.                                                                              Monitor side effects and if necessary choose alternative AB or other hypnotic drugs (not a CYP3A4 substrate).                   3                                                                                                                                                                                 [@dkz221-B211]                       
  *Antifungal agents*                                                                                    voriconazole                                               erythromycin                                                                                       Inhibition of CYP3A4.                                                                                                           Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects. For voriconazole, perform TDM and adjust dose if needed.                               2                                                 [@dkz221-B154] ^,^ [@dkz221-B155]
  itraconazole                                                                                           ciprofloxacin                                              Inhibition of CYP3A4.                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *Antineoplastic drugs*                                                                                 vinorelbine                                                clarithromycin                                                                                     Inhibition of CYP3A4 and P-gp.                                                                                                  Avoid combination or adjust dose of substrates and closely monitor side effects.                                                                                                         1                                                          [@dkz221-B179]
  *Anti-gout drugs*                                                                                      colchicine                                                 clarithromycin                                                                                     Inhibition of CYP3A4.                                                                                                           Avoid combination or perform TDM and adjust dose if needed.                                                                                                                              1                                                          [@dkz221-B180]
  azithromycin                                                                                           Inhibition of CYP3A4.                                      Consider alternative or adjusted dose of substrate or use cautiously by monitoring side effects.   2                                                                                                                               [@dkz221-B180]                                                                                                                                                                                                         
  probenecid                                                                                             ciprofloxacin                                              Inhibition of OAT.                                                                                 Monitor side effects and if necessary adjust dose of substrate.                                                                 3                                                                                                                                                                        [@dkz221-B194] ^,^ [@dkz221-B195]             
  *Anaesthesia drugs*                                                                                    midazolam                                                  clarithromycin, erythromycin                                                                       Inhibition of CYP3A4.                                                                                                           Avoid combination or adjust dose of substrates and closely monitor side effects.                                                                                                         1                                                          [@dkz221-B156]
  ketamine                                                                                               clarithromycin                                             Inhibition of CYP3A4.                                                                              Consider alternative or perform TDM and adjust dose if needed.                                                                  2                                                                                                                                                                                 [@dkz221-B161]                       
  alfentanil                                                                                             erythromycin                                               Inhibition of CYP3A4.                                                                              Monitor side effects and if necessary adjust dose of substrate.                                                                 3                                                                                                                                                                                 [@dkz221-B162]                       
  ropivacaine                                                                                            clarithromycin                                             Inhibition of CYP3A4.                                                                                                                                                                                                                                                                                                                                                                                                                                     
  ciprofloxacin                                                                                          Inhibition of CYP1A2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  midazolam                                                                                              roxithromycin                                              Inhibition of CYP3A4.                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *Analgesics*                                                                                           oxycodone                                                  clarithromycin                                                                                     Inhibition of CYP3A4.                                                                                                           Avoid combination or adjust dose of substrates and closely monitor side effects.                                                                                                         1                                                          [@dkz221-B167]
  *Immunosuppressant drugs*                                                                              cyclosporine                                               erythromycin                                                                                       Inhibition of CYP3A4.                                                                                                           Avoid combination or adjust dose of substrates and perform TDM.                                                                                                                          1                              [@dkz221-B168] ^,^ [@dkz221-B169] ^,^ [@dkz221-B181] ^,^ [@dkz221-B182]
  everolimus                                                                                             erythromycin                                               Inhibition of CYP3A4 and/ P-gp.                                                                                                                                                                                                                                                                                                                                                                                                                           
  tacrolimus                                                                                             levofloxacin                                               Inhibition of CYP3A4 or P-gp.                                                                      Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects.                               2                                                                                                                                                                                 [@dkz221-B170]                       
  cyclosporine                                                                                           ciprofloxacin                                              Inhibition of CYP3A4.                                                                              Monitor side effects and, if necessary adjust dose of substrate.                                                                3                                                                                                                                                                        [@dkz221-B171] ^,^ [@dkz221-B172]             
  *Vasoactive agents*                                                                                    sildenafil                                                 clarithromycin, erythromycin, ciprofloxacin                                                        Inhibition of CYP3A4.                                                                                                           Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects.                                                                                        2                                                 [@dkz221-B173] ^,^ [@dkz221-B174]
  *Appetite suppressants*                                                                                sibutramine                                                clarithromycin                                                                                     Inhibition of CYP3A4 and P-gp.                                                                                                  Avoid combination or adjust dose of substrates and closely monitor side effects.                                                                                                         1                                                 [@dkz221-B175] ^,^ [@dkz221-B176]
  *Emergency birth control*                                                                              ulipristal acetate                                         erythromycin                                                                                       Inhibition of CYP3A4.                                                                                                           Avoid combination or adjust dose of substrates and closely monitor side effects.                                                                                                         1                                                          [@dkz221-B178]
  *Antimalarial agents*                                                                                  halofantrine                                               tetracycline                                                                                       Probably by CYP3A4 inhibition.                                                                                                  Avoid combination or perform TDM and adjust dose if needed.                                                                                                                              1                                                          [@dkz221-B177]
  *Muscle relaxants*                                                                                     tizanidine                                                 ciprofloxacin                                                                                      Inhibition of CYP1A2.                                                                                                           Avoid combination or perform TDM and adjust dose if needed.                                                                                                                              1                                                          [@dkz221-B183]
  *Anti-diarrhoeals*                                                                                     loperamide                                                 TMP/SMX                                                                                            Inhibition of CYP2C8.                                                                                                           Consider alternative or adjusted dose of substrate, or use cautiously by monitoring side effects.                                                                                        2                                                          [@dkz221-B186]
  *Anaemia medications*                                                                                  iron supplements                                           quinolone, tetracyclines                                                                           Complex formation.                                                                                                              Avoid co-administration or administer at interval of at least 2 h.                                                                                                                       2                                                          [@dkz221-B212]
  *Other metal cations*                                                                                  zinc sulfate                                               quinolone, tetracyclines                                                                           Complex formation.                                                                                                              Avoid co-administration or administer at interval of at least 2 h.                                                                                                                       2                                       [@dkz221-B144] ^,^ [@dkz221-B188] ^,^ [@dkz221-B189]
  calcium acetate, calcium carbonate, calcium polycarbophil, patiromer, lanthanum carbonate, sevelamer   quinolone, tetracyclines                                   Complex formation.                                                                                 Administer at interval of at least 2 h.                                                                                         3                                                                                                                                                                        [@dkz221-B139] ^,^ [@dkz221-B190]             
  *Other ABs*                                                                                            linezolid                                                  clarithromycin                                                                                     Inhibition of P-gp.                                                                                                             Consider alternative or perform TDM and adjust dose if needed.                                                                                                                           2                                                          [@dkz221-B196]
  dapsone                                                                                                trimethoprim                                               Inhibition of CYP2C8.                                                                              Monitor side effects and if necessary adjust dose of substrate.                                                                 3                                                                                                                                                                                 [@dkz221-B187]                       
  neomycin                                                                                               penicillin V                                               NA                                                                                                 Consider alternative or adjust dose of penicillin.                                                                              3                                                                                                                                                                                 [@dkz221-B221]                       

All detailed supporting information about each DDI is available in Tables [S1 and S2](#sup1){ref-type="supplementary-material"}.

OCT, organic cation transporter; OAT, organic anion transporter; MATE1, multidrug and toxin extrusion 1; TMP/SMX, trimethoprim/sulfamethoxazole; NA, not available yet.

1, strong interaction; 2, substantial interaction; 3, moderate interaction; 4, weak or no interaction.

We present a step-by-step approach to AB prescribing in COPD: (i) check whether co-morbidity is present; (ii) a quick overview of the AB and its interacting medication, possible interaction mechanism, level of interaction, and practical recommendations is provided in Table [4](#dkz221-T4){ref-type="table"}; and (iii) detailed explanation about related interacting mechanisms and recommendations for the management of related DDIs are provided in the main text.

Mechanisms of DDI
-----------------

An AB can act as an inhibitor/inducer and/or a substrate, producing moderate to strong DDI with other co-administered medication. There are two scenarios: (i) the co-administered drug alters the pharmacokinetic parameters of the AB; and (ii) the AB influences the pharmacokinetic parameters of the co-administered medication. The main mechanisms of these DDIs are complex formation, inhibition/induction of drug-metabolizing enzymes and alteration of drug transporters (Table [4](#dkz221-T4){ref-type="table"}). The ability to inhibit CYP3A4 makes ABs prone to interaction with many different drugs as CYP3A4 metabolizes \>50% of clinically prescribed drugs.[@dkz221-B13]

Information structured according to drugs for comorbidities
-----------------------------------------------------------

The presentation of information on potential clinically significant DDIs with a moderate to strong level of interaction is according to the most frequent comorbidities that have been reported in COPD patients.[@dkz221-B8]^,^[@dkz221-B14] Potential mechanisms of DDIs and actionable recommendations to manage the DDIs are provided in Table [4](#dkz221-T4){ref-type="table"}.

### Diabetes

Patients with COPD have a 50% higher risk of developing diabetes than persons without COPD.[@dkz221-B15] Some antidiabetic drugs are substrates of enzymes such as CYP3A4 (glipizide, tolbutamide), CYP2C9 (glipizide, glyburide) and CYP2C8 (repaglinide), and substrates of drug transporter-like P-glycoprotein (P-gp) transporter (glipizide, glyburide).[@dkz221-B16] ABs such as clarithromycin (CYP3A4 and P-gp inhibitor), trimethoprim/sulfamethoxazole (CYP2C8/2C9 inhibitor) and levofloxacin (P-gp inhibitor) may inhibit the function of these metabolic enzymes and transporters. These ABs can potentially increase the blood concentration of the antidiabetic agents mentioned above.[@dkz221-B16] Consequently, patients may develop hypoglycaemia. Therefore, it is suggested that these combinations should be avoided by substituting a related AB or adjusting the dose of antidiabetic agents as well as monitoring the patients' blood glucose.

### Heart and circulatory system diseases

#### Antihypertensive agents

Hypertension is associated with COPD with a relative risk of 1.6.[@dkz221-B15] Antihypertensive calcium channel blockers (CCBs) such as diltiazem and verapamil are CYP3A4 substrates.[@dkz221-B27] Therefore, macrolides (CYP3A4 inhibitors) can enhance the pharmacological activity of CCBs.[@dkz221-B30] Avoiding the combination by replacement of macrolides or CCBs with another group of drugs or adjusting the dose of CCBs while monitoring blood pressure is recommended. Erythromycin and clarithromycin are the most potent CYP3A4 inhibitors, while azithromycin and roxithromycin are weak inhibitors.[@dkz221-B30]^,^[@dkz221-B31] Hence, if prescribing macrolides, choosing macrolides with minimal inhibitory capacity to be co-prescribed with CCBs may minimize the risk of DDI.

Spironolactone, a potassium-sparing diuretic, is used to lower blood pressure. Combination of spironolactone with trimethoprim/sulfamethoxazole may produce hyperkalaemia because both drugs can inhibit renal excretion of potassium.[@dkz221-B32] Therefore, avoiding this combination (by selecting an alternative AB) or adjusting the dose of spironolactone and closely monitoring potassium plasma levels is strongly recommended.

#### Lipid-lowering drugs

Lipid metabolism problems are among the most prevalent comorbidities in COPD patients.[@dkz221-B14] The main pharmacological approach to the management of blood cholesterol levels is statin therapy.[@dkz221-B33] Some ABs increase the plasma concentration of statins by several mechanisms. Statins such as simvastatin and atorvastatin are biodegraded by CYP3A4.[@dkz221-B34]^,^[@dkz221-B35] Therefore, potent CYP3A4 inhibitors (erythromycin and clarithromycin) increase the risk of statin-related side effects such as rhabdomyolysis.[@dkz221-B34]^,^[@dkz221-B35] Other statins, such as rosuvastatin, pravastatin and fluvastatin, are not CYP3A4 substrates.[@dkz221-B36] However, the hepatic clearance of these statins is facilitated by anion-transporting polypeptides.[@dkz221-B37] These influx transporters facilitate the transport of statins from systemic blood to liver cells to be metabolized or subsequently delivered into the bile for elimination.[@dkz221-B37] Clarithromycin and erythromycin have been reported to be inhibitors of these transporters.[@dkz221-B38] Therefore, replacing erythromycin and clarithromycin with other ABs, temporarily stopping statins or adjusting the dose of statins while monitoring statin-related side effects is recommended.

#### Oral anticoagulants

Both coumarins and direct oral anticoagulants (DOACs) may interact with ABs. Multiple studies reported that DDIs between ABs and coumarins (warfarin, phenprocoumon, acenocoumarol) led to increased risks of haemorrhage.[@dkz221-B39] Several interaction mechanisms were proposed.[@dkz221-B59]^,^[@dkz221-B60] One mechanism is by disruption of intestinal flora that synthesizes vitamin K, as many ABs could alter the balance of gut flora.[@dkz221-B59] Another mechanism is that ABs (e.g. trimethoprim/sulfamethoxazole and macrolides) alter coumarin metabolism, which mainly involves CYP2C9 (trimethoprim/sulfamethoxazole) and CYP3A4 (macrolides).[@dkz221-B60] Therefore, to choose alternative ABs or, if not possible, to monitor international normalized ratio (INR) values and adjust the dose of coumarins is recommended.

DOACs are regarded as a safe alternative to replace coumarins.[@dkz221-B61] However, since some DOACs (edoxaban, rivaroxaban, dabigatran) are substrates of CYP3A4 and/or the P-gp transporter, their AUC values can be increased by ABs such as macrolides.[@dkz221-B62]^,^[@dkz221-B63] Therefore, when macrolides and DOACs are required in combination, careful monitoring of signs of bleeding is needed, and adjusting the dose of DOACs should be done if necessary.

#### Antiarrhythmic agents

Some antiarrhythmic agents, such as digoxin, quinidine, lignocaine and procainamide, potentially interact with ABs.[@dkz221-B64] Quinidine and lignocaine are CYP3A4 substrates and therefore macrolides may inhibit their degradation and increase their bioavailabilities.[@dkz221-B64]^,^[@dkz221-B65] The renal clearance of procainamide and digoxin is inhibited by trimethoprim.[@dkz221-B66]^,^[@dkz221-B67]^,^[@dkz221-B72]^,^[@dkz221-B73] The mechanism of interaction is inhibition of tubular secretion via inhibition of the renal organic cation transporter because they are substrates of the transporter.[@dkz221-B66]^,^[@dkz221-B67]^,^[@dkz221-B72]^,^[@dkz221-B73] Consequently, blood concentrations of these drugs are increased.[@dkz221-B66]^,^[@dkz221-B67]^,^[@dkz221-B72]^,^[@dkz221-B73] Digoxin is a substrate of the P-gp transporter.[@dkz221-B68] Clarithromycin could elevate the AUC of digoxin, which may cause toxicities.[@dkz221-B68] Since quinidine, lignocaine, digoxin and procainamide are drugs with an NTI, avoiding ABs that can lead to DDIs with these drugs is recommended.[@dkz221-B76]^,^[@dkz221-B77] However, if their co-prescription is necessary, therapeutic drug monitoring (TDM) of these antiarrhythmic agents is strongly recommended.[@dkz221-B77]

Respiratory diseases
--------------------

### Medication for obstructive airways diseases

One of the most prevalent comorbidities in COPD is asthma.[@dkz221-B14] Some anti-asthma drugs, such as methylprednisolone, montelukast, loratadine, roflumilast and theophylline, are substrates of CYP3A4 and/or the P-gp transporter and have been shown to interact with macrolides.[@dkz221-B78] Hence, one might consider other ABs for combination with asthma drugs, or closely monitor patients, especially in the case of theophylline, which is an NTI drug.[@dkz221-B88] As theophylline is also metabolized by CYP1A2,[@dkz221-B89] ciprofloxacin (a CYP1A2 potent inhibitor) should be avoided.[@dkz221-B90]

### Antimycobacterial agents

Tuberculosis and COPD share comparable risk factors and therefore can co-occur in individuals, particularly elderly patients.[@dkz221-B98] Rifampicin and rifabutin (antimycobacterial agents) work as potent inducers of hepatic and intestinal CYP enzymes.[@dkz221-B99] They can markedly reduce the activities of clarithromycin, doxycycline and trimethoprim/sulfamethoxazole by causing their rapid elimination.[@dkz221-B100] Since rifampicin also exhibits other AB properties, such as activity against MRSA in combination with other drugs, rationalizing antimicrobial therapy should be considered accordingly.[@dkz221-B105] Alternative ABs for treating COPD are also recommended to reduce the risk of treatment failures.

Moxifloxacin might be an alternative AB for clarithromycin, doxycycline and trimethoprim/sulfamethoxazole owing to its moderate or weak interaction with rifampicin.[@dkz221-B106] Moxifloxacin is not metabolized by CYP450 and its interacting mechanisms with rifampicin might be facilitated by induction of other enzymes, such as uridine diphosphate-glucuronosyltransferases and sulfotransferases.[@dkz221-B106]

Rifabutin and rifampicin are CYP substrates. Rifabutin is a CYP3A4 substrate, and therefore macrolides may increase its serum concentration and enhance the risk of related ADR.[@dkz221-B101]^,^[@dkz221-B110]^,^[@dkz221-B111] Another study reported that rifampicin concentrations in blood are moderately elevated by co-trimoxazole.[@dkz221-B104] It was assumed that the interaction was facilitated by inhibition of mixed-function oxidases, which are responsible for metabolizing rifampicin.[@dkz221-B104] Thus, considering alternative ABs or monitoring the clinical and biochemical parameters for rifampicin-related hepatotoxicity is suggested when rifampicin and co-trimoxazole are combined.

It should be mentioned that not all the drugs for atypical *Mycobacterium* spp. were included in this review because selection was limited to ABs that are used frequently among COPD patients. For drugs outside the scope of this review, other references (e.g. statements of product characteristics) need to be considered.

Neurological disorders
----------------------

### Anti-Parkinson's drugs

Bromocriptine and cabergoline (dopamine agonists) are substrates of CYP3A4 and/or the P-gp transporter.[@dkz221-B112]^,^[@dkz221-B113] Co-prescription of these drugs with clarithromycin and erythromycin may produce major interactions and therefore might lead to toxicities.[@dkz221-B112]^,^[@dkz221-B113] Thus, avoiding such combinations is recommended. However, if this is not possible, adjusting the dose of these Parkinson's medications and closely monitoring side effects are needed.

### Antiepileptic drugs

Carbamazepine, phenytoin and phenobarbital can stimulate the activity of a variety of CYP (CYP1A2/2C9/3A4) and glucuronyl transferase enzymes, which results in multiple DDIs with other substrates for these enzymes.[@dkz221-B114] Carbamazepine and phenytoin were reported to reduce the half-life of doxycycline by stimulating the hepatic metabolism of doxycycline.[@dkz221-B117] It is suggested that an alternative AB should be considered or that the dose of antiepileptic drugs should be adjusted while monitoring the AB activity of doxycycline.

Carbamazepine and phenytoin are substrates of CYP1A2/3A4 and CYP2C8, respectively. A CYP1A2/3A4 inhibitor (ciprofloxacin) and a CYP2C8 inhibitor (trimethoprim) were reported to increase the bioavailability of carbamazepine and phenytoin, respectively.[@dkz221-B116] Moreover, phenytoin is an NTI drug and therefore avoiding using trimethoprim concomitantly or performing TDM of phenytoin is recommended when this DDI is not avoidable.[@dkz221-B120]

Ciprofloxacin was reported to increase the AUC of carbamazepine by \>50%.[@dkz221-B118] Although it is not clear whether carbamazepine can be considered to be an NTI drug, a rising carbamazepine plasma concentration because of this DDI needs special caution.[@dkz221-B121] Dose adjustment and TDM of carbamazepine are suggested to diminish potential toxicities.

Depression and psychiatric disorders
------------------------------------

Depression and psychiatric disorders are common among COPD patients.[@dkz221-B14] Some antidepressant (trazodone), anxiolytic (buspirone) and antipsychotic (quetiapine, and pimozide) drugs are CYP3A4 substrates and therefore might trigger clinically relevant DDIs with ABs.[@dkz221-B122] Erythromycin and clarithromycin increased the AUCs of these drugs substantially.[@dkz221-B122] Considering alternative ABs or adjusting the dose of substrates and monitoring related side effects is the way to control potential ADR.

CYP3A4 is also responsible for metabolizing diazepam, in addition to CYP2C19.[@dkz221-B126] Ciprofloxacin was reported to decrease diazepam clearance moderately by inhibiting CYP3A4 activity.[@dkz221-B127] Monitoring diazepam-related side effects can therefore be considered when this combination is prescribed.

Ciprofloxacin is also a potent CYP1A2 inhibitor.[@dkz221-B128] Therefore, metabolism of an atypical antipsychotic, clozapine, a CYP1A2 substrate with an NTI, can be altered by ciprofloxacin, which produces a significant increase in clozapine serum concentration.[@dkz221-B129]^,^[@dkz221-B130] Replacing ciprofloxacin or TDM of clozapine is an option that can be chosen in managing this DDI.

Dyspepsia
---------

Drugs containing metal cations (e.g. antacids, sucralfate and bismuth salts) produced chemical interactions with some ABs, such as oral tetracyclines (e.g. tetracycline, doxycycline) and fluoroquinolones (e.g. ciprofloxacin, moxifloxacin).[@dkz221-B131] Tetracyclines have a strong tendency to form chelates due to their structural features, which include many chelation sites.[@dkz221-B145] Meanwhile, fluoroquinolones have two main sites of metal chelation: 4-keto oxygen and 3-carboxylic acid groups.[@dkz221-B146]

The formation of metal ion chelation complexes decreases absorption of tetracycline and fluoroquinolones, and this reduced bioavailability may lead to ineffectiveness of these ABs.[@dkz221-B131] Therefore, it is recommended that their combination should be avoided by replacing tetracyclines and fluoroquinolones with another AB, e.g. amoxicillin or amoxicillin/clavulanic acid. It was reported that antacids did not affect the bioavailability of amoxicillin and amoxicillin/clavulanic acid when they were co-administered.[@dkz221-B136] If replacement of the AB is not possible, replacement of antacids, sucralfate or bismuth salts with a proton pump inhibitor (PPI) is also favoured. Another alternative is to separate administration by using quinolone or tetracycline at least 2 h before or 6 h after the dyspepsia drugs.

When considering a PPI, lansoprazole may not be the best alternative as it is partly metabolized by CYP3A4 and has been found to interact with clarithromycin.[@dkz221-B147]

HIV
---

HIV-positive patients have an ∼50% higher risk of developing COPD than HIV-negative patients.[@dkz221-B148] Thus, the risk of co-prescriptions for treating these chronic conditions may also be high. A protease inhibitor (saquinavir) and NRTIs (didanosine and lamivudine) were found to clinically interact with ABs.[@dkz221-B149]

Didanosine is very acid sensitive, and therefore didanosine formulations are supplemented with buffering mixtures containing magnesium hydroxide, dihydroxyaluminium sodium carbonate and sodium citrate to prevent hydrolysis by gastric acid.[@dkz221-B149] These metal ions may form chelation complexes with quinolones and reduce their serum concentration.[@dkz221-B149]^,^[@dkz221-B150] Two studies confirmed the didanosine and ciprofloxacin interaction, and recommended that when co-administration cannot be avoided, ciprofloxacin must be given at least 2 h before didanosine.[@dkz221-B149]^,^[@dkz221-B150]

Trimethoprim/sulfamethoxazole may inhibit clearances of didanosine and lamivudine by competitively hindering their renal secretion.[@dkz221-B152]^,^[@dkz221-B153] Consequently, AUCs of didanosine and lamivudine are elevated moderately.[@dkz221-B152]^,^[@dkz221-B153] Monitoring of the presumed side effects should be performed.

Saquinavir is metabolized by CYP3A4 and the presence of erythromycin increased its AUC by almost 100%.[@dkz221-B151] Choosing an alternative AB or adjusting the dose of saquinavir while monitoring toxicities can be considered as a means of managing this DDI.

Other potential clinically significant DDIs
-------------------------------------------

Some other drugs that have indications for comorbidities in COPD patients were found to interact with ABs. Some individual drugs of different classes (e.g. voriconazole and vinorelbine) are metabolized by CYP3A4.[@dkz221-B154] Therefore, their metabolism is interfered with by CYP3A4 inhibitors (macrolides).[@dkz221-B154] Other drugs are CYP1A2 substrates (e.g. ropivacaine and tizanidine) and therefore potent inhibitors of CYP1A2, such as quinolones, significantly alter their metabolism and elevate their bioavailabilities.[@dkz221-B164]^,^[@dkz221-B183] Others are CYP2C8 substrates (e.g. loperamide for diarrhoea) and therefore trimethoprim (a potent CYP2C8 inhibitor) inhibits their clearance and increases their AUC values.[@dkz221-B186]^,^[@dkz221-B187] Some drugs containing metal cations (e.g. Fe, Zn, Ca) should be avoided or administered with a separation of at least 2 h from quinolones and tetracyclines.[@dkz221-B139]^,^[@dkz221-B144]^,^[@dkz221-B188] Other interactions were facilitated by drug transporters. A uricosuric agent (probenecid) interacts moderately with ciprofloxacin via competitive inhibition of organic anion transporters in renal tubules.[@dkz221-B194]^,^[@dkz221-B195] Moreover, linezolid, which is a substrate of the P-gp transporter, can potentially produce clinically significant interaction with P-gp inhibitors (macrolides).[@dkz221-B196]

### DDIs related to NTIs

Some ABs may interact with NTI drugs and therefore can produce serious ADRs. The NTI drugs in this review include CYP3A4 substrates (theophylline, ketamine, everolimus, tacrolimus, halofantrine, lignocaine, quinidine, voriconazole, carbamazepine, warfarin, cyclosporine, colchicine, phenprocoumon/acenocoumarol); CYP1A2 substrates (theophylline, carbamazepine, clozapine, tizanidine); CYP2C9 substrates and drugs sensitive to alterations in the normal gut flora (warfarin, phenprocoumon/acenocoumarol); a CYP2C8 substrate (phenytoin); substrates of the P-gp transporter (digoxin, linezolid); and a substrate of the organic cation transporter (procainamide).[@dkz221-B76]^,^[@dkz221-B77]^,^[@dkz221-B88]^,^[@dkz221-B120]^,^[@dkz221-B197]

Discussion
==========

Included articles
-----------------

This study outlines the possible DDIs related to frequently prescribed ABs in COPD patients from clinical and observational studies. We only included well-designed studies (≥2 points) since they provide more valid evidence than studies without a control or comparison group (0 or 1 point). DDIs based on case reports or hypotheses may lead to unnecessary warnings if these are not confirmed by well-designed studies. One classic example of this point is ABs and oral contraceptive interactions; many cases of unintended pregnancies were reported after ABs were prescribed to women on oral contraceptives, which attracted much attention from health practitioners.[@dkz221-B198]^,^[@dkz221-B199] After scientific evidence from clinical and pharmacokinetic studies has consistently and repeatedly failed to support such interaction, the warning about DDIs between hormonal contraception and non-rifampicin ABs has finally been cancelled in related guidelines.[@dkz221-B199]

Mechanisms of DDI
-----------------

A DDI of potential clinical significance between an AB and a co-administered medication may occur in two situations: (i) the co-administered drug influences the absorption, distribution, metabolism and elimination (ADME) of the AB; and (ii) the AB influences the ADME of the co-administered medication. When the AB acted as a substrate, some co-administered drugs reduced the blood concentration of the AB and led to failure of the AB treatment to reduce COPD exacerbations. Other co-administered drugs increased the blood concentration of the AB, which could result in the termination of AB use because of an ADR, and therefore acted against the control of infection. Acting as inhibitors, ABs could also increase the blood concentrations of co-administered drugs, which may also produce an ADR and lead to termination of co-administered drugs, and therefore may lead to failure of treatment of comorbidities. Thus, DDIs related to ABs may hinder effective infection control and exacerbation management among COPD patients as well as treatment of comorbidities in COPD.

Comorbidities among COPD patients
---------------------------------

The impact of comorbidities on quality of life in COPD patients is well reported; however, potential drug interactions between drugs for these comorbidities and ABs used for COPD have received little specific attention. From this review, we found that many drugs (e.g. those used for heart and circulatory system diseases) should not be co-administered with related ABs, and other actions are necessary, such as dose adjustment, choosing an alternative drug and monitoring ADRs. These drug interactions may not only influence treatment options for clinical practitioners but also influence treatment effects for both COPD and comorbidities.

Information collected in this review can be used as input to improve the sensitivity and specificity of DDI alert systems. Moreover, this study may also be attractive for researchers in this field who may take into account the availability of high-quality studies when evaluating the evidence for many potential interactions.

Special warning for NTI drugs
-----------------------------

We found that some NTI drugs might potentially interact with ABs. Because of the narrow separation between effective and toxic dosing of these drugs, a small alteration of their pharmacokinetic parameters can produce fatal consequences.[@dkz221-B88]^,^[@dkz221-B120] Therefore, combination with particular ABs that have an ability to inhibit their clearance pathways should be avoided if possible. However, if the benefits of combination outweigh the potential side effects, dose adjustment and performing TDM of the NTI drugs are strongly recommended.

Limitations
-----------

Some limitations of this review are worth mentioning. First, although we reviewed a significant part of the literature, we did not include all sources that might indicate relevant DDIs, such as case reports, summary of product characteristics and theoretical hypotheses. As a result, we did not find some DDIs that are considered serious and clinically highly relevant, such as QT-interval prolonging interactions for combinations of macrolides with other QT-prolonging drugs or the risk of pseudotumour cerebri in the case of combinations of doxycycline with vitamin A analogues.[@dkz221-B200]^,^[@dkz221-B201] Such interactions are commonly found as case reports, as it is unethical to design studies to confirm these serious risks in clinical studies. However, for some DDIs it is possible to study the clinical manifestation of a potential DDI in an observational study using real-world drug utilization data.[@dkz221-B202] Secondly, selection of the ABs included in this review was based on their frequent use in COPD and therefore information for other ABs used for COPD comorbidities, such as atypical *Mycobacterium* spp., is limited, and this may restrict the scope of application of this review. Thirdly, due to limited comparative analyses for several specific DDIs included in this review, it may be difficult to make recommendations for a specific situation. Our classification of DDI levels only offers a general consideration. The specific impact of a DDI is determined by many variables, such as different doses and formulations and the comorbidities of patients. Therefore, case-by-case analysis is important in clinical practice and a drug interaction handbook such as *Stockley's Drug Interactions*[@dkz221-B203] further expands on these issues.

Conclusions
===========

Clinically significant DDIs related to ABs may involve a wide range of indicated drugs to treat comorbidities in COPD. Clinicians should pay attention to these drug interactions when prescribing ABs in order to reduce the frequency and severity of exacerbations in COPD patients and take necessary actions to ensure therapeutic effect and safety of patients. This study may contribute to better prescribing of ABs to COPD patients with comorbidities where potentially interacting drug combinations may be used. Furthermore, the information may highlight gaps in scientific knowledge about potential adverse effects from DDIs.
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